Fulcrum Therapeutics:终止镰状细胞病药物Pociredir后批准重组计划 - 美国证券交易委员会文件披露

美股速递
Jun 05

Fulcrum Therapeutics在一份提交给美国证券交易委员会的文件中披露,公司已批准一项重组计划。此决定是在其终止针对镰状细胞病的在研药物Pociredir的开发之后作出的。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10